Morphle Labs Inc., a Bengaluru-headquartered deep-tech startup focused on revolutionizing cancer diagnostics, has secured USD 5 million in Series A funding led by Inflexor Ventures. This fresh investment marks a significant milestone in the company’s plan to drive global adoption of automated histopathology systems designed to make cancer detection faster, more scalable, and more reliable.
The newly infused capital will be used to ramp up global market expansion, scale device manufacturing capabilities, and fast-track regulatory approvals for its portfolio of medical diagnostic hardware. With operations already supporting laboratories in the United States and Europe, Morphle Labs is now preparing for broader commercialization across high-demand geographies.
A major focus of the deployment will be boosting production of Morphle’s flagship technologies — RoboTome and MorphoLens. RoboTome is a robotic microtome engineered to cut biopsy tissue blocks at high precision and more than double the speed of expert histotechnologists. MorphoLens complements this by digitizing pathology slides at scale, scanning over 100 slides per hour through advanced optics and AI-driven imaging. Together, these solutions target the most labor-intensive areas of histology — creating a seamless, automated workflow that improves throughput, consistency, and diagnostic accuracy in pathology labs.
Morphle Labs is led by CEO Rohit Hiwale, CTO Ashish Manmode, and COO Sunnel Daniel, who collectively bring strong expertise in robotics, medical technology, and deep-tech commercialization. The company has steadily built a strong intellectual property foundation — with more than 80 patents filed — reflecting its commitment to breakthrough innovation in clinical automation.
Currently operating with nearly 100 employees across Bengaluru and Boston, Morphle Labs intends to expand its workforce across robotics engineering, optical design, computer vision, and regulated software manufacturing. The long-term vision is to build a new generation of automation technologies that support faster diagnostic turnaround times and help clinicians deliver better outcomes for cancer patients worldwide.
With this funding round, Morphle Labs strengthens its position as a global innovator in pathology automation, aiming to redefine how cancer diagnoses are performed and delivered at scale.
